Stephen B. Shohet Sells 7,862 Shares of Amphastar Pharmaceuticals, Inc. (AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $18.04, for a total value of $141,830.48. Following the transaction, the director now owns 31,978 shares in the company, valued at approximately $576,883.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Amphastar Pharmaceuticals, Inc. (NASDAQ AMPH) traded up $0.23 on Friday, reaching $18.38. The company’s stock had a trading volume of 115,080 shares, compared to its average volume of 210,505. Amphastar Pharmaceuticals, Inc. has a 52 week low of $12.05 and a 52 week high of $21.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. The stock has a market capitalization of $845.04, a price-to-earnings ratio of 122.53 and a beta of 1.68.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The company had revenue of $57.90 million for the quarter, compared to analyst estimates of $57.23 million. During the same quarter in the previous year, the firm earned $0.14 earnings per share. The firm’s quarterly revenue was down 9.8% compared to the same quarter last year. research analysts predict that Amphastar Pharmaceuticals, Inc. will post -0.03 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals announced that its Board of Directors has authorized a stock repurchase program on Wednesday, August 9th that allows the company to repurchase $20.00 million in shares. This repurchase authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “Stephen B. Shohet Sells 7,862 Shares of Amphastar Pharmaceuticals, Inc. (AMPH) Stock” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://sportsperspectives.com/2017/11/19/stephen-b-shohet-sells-7862-shares-of-amphastar-pharmaceuticals-inc-amph-stock.html.

Several brokerages have recently commented on AMPH. Piper Jaffray Companies set a $20.00 price target on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, July 29th. BidaskClub lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. BMO Capital Markets reiterated a “hold” rating and issued a $16.00 target price on shares of Amphastar Pharmaceuticals in a research note on Monday, July 31st. ValuEngine lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $19.00 target price (down previously from $20.00) on shares of Amphastar Pharmaceuticals in a research note on Friday, August 11th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has an average rating of “Hold” and an average target price of $20.43.

A number of hedge funds and other institutional investors have recently modified their holdings of AMPH. Victory Capital Management Inc. boosted its holdings in Amphastar Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock worth $100,000 after acquiring an additional 842 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Amphastar Pharmaceuticals in the second quarter worth about $111,000. State of Alaska Department of Revenue boosted its holdings in Amphastar Pharmaceuticals by 77.2% in the second quarter. State of Alaska Department of Revenue now owns 7,052 shares of the company’s stock worth $125,000 after acquiring an additional 3,072 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its holdings in Amphastar Pharmaceuticals by 2.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock worth $151,000 after acquiring an additional 230 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its holdings in Amphastar Pharmaceuticals by 58.2% in the second quarter. BNP Paribas Arbitrage SA now owns 10,545 shares of the company’s stock worth $188,000 after acquiring an additional 3,880 shares in the last quarter. 43.89% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply